



HHS Public Access

Author manuscript

Mol Psychiatry. Author manuscript; available in PMC 2016 September 19.

Published in final edited form as:

Mol Psychiatry. 2016 February ; 21(2): 270–276. doi:10.1038/mp.2015.32.

Whole genome association analysis of treatment response in obsessive-compulsive disorder

H Qin¹, JF Samuels², Y Wang², Y Zhu¹⁹, MA Grados², MA Riddle², BD Greenberg³, JA Knowles⁴, AJ Fyer⁵, JT McCracken⁶, DL Murphy⁷, SA Rasmussen³, BA Cullen², J Piacentini⁶, D Geller⁸, SE Stewart⁹, D Pauls³, OJ Bienvenu², FS Goes², B Maher², AE Pulver¹¹, D Valle¹², C Lange^{13,14}, M Mattheisen^{13,14,15}, NC McLaughlin¹⁶, K-Y Liang¹⁰, EL Nurmi¹⁷, KD Askland¹⁸, G Nestadt², and YY Shugart¹

¹Unit on Statistical Genomics, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA

²Department of Psychiatry and Behavioral Sciences, School of Medicine, Johns Hopkins University, Baltimore, Maryland 21205, USA

³Department of Psychiatry and Human Behavior, Brown Medical School, Butler Hospital, Brown University, Providence, RI 02906, USA

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

Corresponding to: Yin Yao Shugart Building 35, Room 3A1000 35 Convent Drive MSC3726 Unit on Statistical Genomics, Division of Intramural Research Programs National Institute of Mental Health, NIH, Bethesda, MD 20892, USA Telephone: 301-496-4341

Fax: 301-480-0673 yin.yao@nih.gov

Haide Qin, Ph.D qinh2@mail.nih.gov

Jack Samuels, Ph.D jacks@jhmi.edu

Yin Wang, M.S. ywang37@jhem.jhmi.edu

Marco A. Grados, M.D. mjgrados@jhmi.edu

Mark A. Riddle, M.D. mriddle@jhmi.edu

Benjamin D. Greenberg, M.D., Ph.D. Benjamin_Greenberg@brown.edu

James A. Knowles, M.D., Ph.D knowles@med.usc.edu

Abby J. Fyer, M.D. ajfyer@pi.cpmc.columbia.edu

James T. McCracken, M.D. jmccracken@mednet.ucla.edu

Dennis L. Murphy, M.D. dm30h@nih.gov

Steven A. Rasmussen, M.D. Steven_Rasmussen@Brown.edu

Bernadette Cullen bcullen@jhmi.edu

John Piacentini, Ph.D. jpiacentini@mednet.ucla.edu

Yun Zhu, Ph.D. yzhu5@tulane.edu

Dan Geller, M.D. dageller@partners.org

S. Evelyn Stewart, M.D. evelyn.stewart@ubc.ca

David L. Pauls, Ph.D. dpauls@pngu.mgh.harvard.edu

O. Joseph Bienvenu, M.D., Ph.D jbienven@jhmi.edu

Fernando S. Goes fgoes1@jhmi.edu

Brion Maher, Ph.D. bmaher@jhsph.edu

Ann E. Pulver aepulver@jhmi.edu

David Valle, M.D. dvalle@jhmi.edu

Christoph Lange, Ph.D. clange@hsph.harvard.edu

M Mattheisen, MD mm@hum-gen.au.dk

Nicole C. McLaughlin, Ph.D. nicole_mclaughlin@brown.edu

K-Y Liang, PhD Kyliang@yhsph.edu

Erica Nurmi, M.D., Ph.D. enurmi@ucla.edu

Kathleen D. Askland, MD kathleen_askland@brown.edu

Gerald Nestadt, M.D. gnestadt@jhmi.edu

CONFLICT OF INTEREST

The authors declare no conflict of interest related to this work.

Supplementary information is available at *Molecular Psychiatry's* website.

⁴Department of Psychiatry, Keck Medical School, University of Southern California, Los Angeles, CA 90089, USA

⁵College of Physicians and Surgeons at Columbia University, 630 West 168th Street, New York, NY 10032

⁶Department of Psychiatry and Biobehavioral Sciences, School of Medicine, University of California, Los Angeles, CA 90095, USA

⁷Laboratory of Clinical Science, NIMH, NIH, Bethesda, MD 20892, USA

⁸Departments of Psychiatry and Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA

⁹Department of Psychiatry, University of British Columbia, A3-118, West 28th Avenue, Vancouver, BC, Canada V5Z 4H4

¹⁰Johns Hopkins University Bloomberg School of Public Health, Department of Mental Health, Baltimore, MD 21205, USA

¹¹Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, Baltimore, MD 21205, USA

¹²Hopkins University School of Medicine, Institute of Human Genetics, Departments of Pediatrics, Ophthalmology and Molecular Biology & Genetics, Baltimore, MD 21205, USA

¹³Harvard School of Public Health, Department of Biostatistics, Boston, MA 02114, USA

¹⁴Department of Genomic Mathematics, University of Bonn, Bonn 53113, Germany

¹⁵Department of Biomedicine and Center for Integrated Sequencing (iSEQ), Aarhus University, Aarhus 8000, Denmark

¹⁶Department of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI 02903, USA

¹⁷Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Jane & Terry Semel Institute of Neuroscience and Human Behavior, 760 Westwood Plaza, Los Angeles, CA 90095, USA

¹⁸Department of Psychiatry and Human Behavior, Butler Hospital, The Warren Alpert School of Medicine of Brown University, Providence, Rhode Island 02903, USA

¹⁹Department of Epidemiology, Tulane University, School of Public Health and Tropical Medicine, New Orleans, LA 70112, USA

Abstract

Up to 30% of patients with obsessive-compulsive disorder (OCD) exhibit an inadequate response to serotonin reuptake inhibitors (SRIs). To date, genetic predictors of OCD treatment response have not been systematically investigated using genome-wide association study (GWAS). To identify specific genetic variations potentially influencing SRI response, we conducted a GWAS study in 804 OCD patients with information on SRI response. SRI response was classified as

“response” ($n = 514$) or “non-response” ($n = 290$), based on self-report. We used the more powerful Quasi-Likelihood Score Test (the MQLS test) to conduct a genome-wide association test correcting for relatedness, and then used an adjusted logistic model to evaluate the effect size of the variants in probands. The top SNP was rs17162912 ($P = 1.76 \times 10^{-8}$) which is near the *DISP1* gene on 1q41-q42, a microdeletion region implicated in neurological development. The other six SNPs showing suggestive evidence of association ($P < 10^{-5}$) were rs9303380, rs12437601, rs16988159, rs7676822, rs1911877, and rs723815. Among them, two SNPs in strong linkage disequilibrium, rs7676822 and rs1911877, located near the *PCDH10* gene, gave p-values of 2.86×10^{-6} and 8.41×10^{-6} , respectively. The other 35 variations with signals of potential significance ($P < 10^{-4}$) involve multiple genes expressed in the brain, including *GRIN2B*, *PCDH10*, and *GPC6*. Our enrichment analysis indicated suggestive roles of genes in the glutamatergic neurotransmission system (FDR = 0.0097) and the serotonergic system (FDR = 0.0213). While the results presented may provide new insights into genetic mechanisms underlying treatment response in OCD, studies with larger sample sizes and detailed information on drug dosage and treatment duration are needed.

Keywords

Obsessive-Compulsive Disorder; Serotonin Reuptake Inhibitors; Genome Wide Association Study; Pharmacogenetics

INTRODUCTION

Approximately 1-3% of the US population suffers from obsessive-compulsive disorder (OCD), a neuropsychiatric disorder characterized by recurrent obsessions and/or compulsions that cause marked distress and impairment.¹ OCD often aggregates in families, and results from segregation analysis and twin studies support significant genetic influence.² A genome-wide linkage study identified several OCD susceptibility loci (i.e., 3q, 7p, 1q, 15q and 6q).³ Variants in several genes have been associated with OCD, including *SLC1A1*⁴, *SLC6A4*^{5,6}, and *GRIN2B*⁷⁻⁹. Prior to the advent of the GWAS platform, association studies targeted a set of candidate genes that were inconsistently reported to be associated with OCD.¹⁰ More recently, two genome-wide association studies have identified *PTPRD*, *DLGAP1*, *CDH10*, and *GRIK2* as potential OCD susceptible loci.^{11, 12}

Individuals affected with OCD are typically treated with a combination of exposure response prevention (ERP) and medications; serotonin reuptake inhibitors (SRIs) are the first-line pharmacotherapy option for the treatment of OCD. However, up to 30% of patients treated with these medications show poor or no response to standard treatment; and some patients cannot tolerate adverse effects of medications.¹³ The literature on genetic predictors of SRI treatment response in OCD is sparse.¹⁴⁻¹⁶ Therefore, elucidation of genetic variants influencing treatment response is needed.

SRIs inhibit the reuptake of the neurotransmitter serotonin by presynaptic cells, thereby increasing extracellular levels of serotonin in the synaptic cleft and allowing serotonin to more easily bind to the postsynaptic receptor.^{6, 17} More than 60 proteins are known to play a role in the serotonin signaling pathway. Among these, the serotonin transporter gene

SLC6A4 may impact SRI response.⁶ In addition, genetic variants in several other genes (i.e., *CYP2D6*, *SLC1A1*, *SLC6A4*, *HTR1B* receptor, *5-HT2A* receptor, and *BDNF*) have been reported to influence SRI response in OCD.¹⁶ However, many of these studies were hampered by small sample sizes and a limited number of known genetic variations in candidate genes. Additionally, analytical approaches vary widely among different studies, which may have led to inconsistent results. In 2012, Tansey et al. reported results from the first genome wide association study (GWAS) of SRI response in major depression.¹⁸ However, to our knowledge, no GWAS study of medication response in OCD has been reported. Therefore, an important unexplored research question is whether genetic variations influence SRI treatment response in OCD.

To address this question, we performed a whole genome association analysis on response to SRIs in 804 OCD cases, using a novel, more powerful Quasi-Likelihood Score Test to correct for the relatedness. Here we report our findings of genome-wide association analysis of therapeutic response of OCD as well as the results of enrichment analysis of nervous system pathways.

MATERIALS AND METHODS

Subject recruitment and data collection

The sample for the current analysis was recruited as part of the OCD Collaborative Genetics Association Study (OC GAS). Detailed methods for OCD diagnosis and sample description have been previously described.^{19, 20} In brief, the evaluation of OCD and drug response was conducted by PhD-level clinical psychologists using a semi-structured diagnostic instrument (SCID), and included the Yale -Brown Obsessive Compulsive Scale (YBOCS) OCD symptom checklist and YBOCS OCD severity scale.²¹ Final DSM-IV (The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition) OCD diagnosis was assigned by consensus of clinicians at each study site and reviewed at Johns Hopkins University.

The individuals in the current study had participated in one of two multisite, collaborative family/genetic studies of OCD, which have been described in detail elsewhere. In brief, the OCD Collaborative Genetics Study (OC GS) (2001-2006), targeted recruitment on families with OCD-affected sibling pairs, and extended these when possible through affected first- and second-degree relatives.¹⁹ The OCD Collaborative Genetic Association Study (OC GAS) (2007-2012) targeted recruitment on trios (i.e., an affected proband and both parents), but also included pedigrees with a proband and unaffected sibling, as well as families with multiple-affected members.¹² Participants were recruited into the studies from outpatient and inpatient clinics, referrals from clinicians in the community, web sites, media advertisements, self-help groups, and annual conventions of the International Obsessive Compulsive Foundation.

As part of the treatment history section of the clinical interview, examiners asked participants about their duration of medication use, maximum dosage, and response to each of several SRI medications (if received), including clomipramine, citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine, and duloxetine. Examiners also asked about response to other medications and behavioral therapy.

Treatment response was initially assessed using a five-point scale of “no response”, “could not tolerate”, “minimal”, “moderate improvement”, and “total remission”. For the current analyses, we dichotomized treatment response into “response” (“moderate improvement” or “total remission”) and “non-response” (“no response” or “minimal response”) categories; those reporting “couldn’t tolerate” and those with missing data on drug response were excluded from the analyses. For those patients who were treated with multiple SRI medications, response was based on the medication to which the best response was reported.

Blood samples were collected from affected probands, their parents, and their affected relatives. DNA samples were extracted using the Qiagen DNA extraction Kit and stored at -80°C for further genotyping. The current analyses included 804 OCD cases who were participants of the OCGAS GWAS. The study was approved by the institutional review board at each participating institution.

Genotyping and quality control

Genotyping was conducted with the Illumina HumanOmniExpress-12v1 (San Diego, CA, USA), in which genotyping was attempted for 730,525 SNPs. Quality control was performed in PLINK to remove poorly genotyped SNPs and individuals. Details of the quality control on the original data have been previously described.¹² To detail, technically failed SNPs were removed. Individuals with sex discrepancy were either removed or updated. The relationship information was corrected and individuals with excess of genotyping errors were removed. Outliers were removed based on a multidimensional scaling (MDS) analysis. We included all OCD patients from the initial quality controlled dataset for subsequent study. Further quality re-assurance and filtering were conducted, including SNPs with Hardy-Weinberg equilibrium (HWE) test p-value $<10^{-6}$ were excluded; SNPs with genotyped rate $<98\%$ or with minor allele frequency (MAF) <0.05 were excluded; SNPs violating Mendelian errors were treated as missing. After genotyping quality control, 53 individuals who could not tolerate the medications were removed, along with 741 individuals that did not have any information on drug effect. The affected individuals with informative drug response data were subjected to an association test. Finally, a total of 804 individuals (including 514 responders and 290 non-responders) were subjected to statistical analysis.

Statistical methods and integrated analysis using bioinformatics resource

We used the more powerful Quasi-Likelihood Score test, termed MQLS test²², to conduct association tests correcting for the relatedness coefficients (based on identity-by-descent, IBD). A sex- and age-adjusted logistic model was used for the evaluation of effect size in probands using the PLINK software.²³ Since the association test could underestimate true signals of association with SRI response due to limited statistical power, all variations with MQLS test p-values $<10^{-4}$ with relatively large effect-size (odds ratios ≥ 1.50 for the risk allele) were reported. All statistical procedures were conducted using in-house R scripts on a GentOS based Cluster computer.

SNP annotation was conducted using a web-based software SNP-NEXUS²⁴ (<http://www.snp-nexus.org>) based on dbSNP135/hg19. Cross references to other GWAS association

studies were explored using the NHGRI GWAS Catalogue.²⁵ Neurobiological evidence was examined in peer-reviewed publications in the PubMed database. LD plots were completed using the LocusZoom software based on 1000 genome CEU population data (hg19/1000 Genomes Mar 2012 EUR).²⁶

Imputation around one SNP of interest was conducted using the Impute2 software (URL: https://mathgen.stats.ox.ac.uk/impute/impute_v2.html) using 1000 Genomes Phase 1 as reference panel (Jun 2011 version). After the imputation, data quality control (QC) was performed to exclude imputed SNPs with genotyping rate <0.95, or significantly deviate from HWE test (p-value <10⁻⁶), or minor allele frequency (MAF) <0.01. Genotypes detected with Mendelian error were set to missing. After QC, MQLS test was performed using the same options described above.

Power calculation was conducted using the GPC software²⁷ (URL: <http://pngu.mgh.harvard.edu/~purcell/gpc/cc2.html>) to indicate the power of the association test given our sample size. We performed a pathway analysis using all SNPs passing QC checkup. Functional enrichment analysis was conducted in ten nervous system pathways defined by the KEGG (Kyoto Encyclopedia of Genes and Genomes) databases using DAVID Bioinformatics Resource v6.7 (URL: <http://david.abcc.ncifcrf.gov/>).²⁸ A total of 8,182 genes in both our dataset and pathway databases were used as the reference background list. Gene-level p-values were calculated by summarizing the SNP-level statistics using MAGENTA software (version 2.4)²⁹, corrected for total number of SNPs in the gene, gene size, as well as the LD patterns in the genes (URL: <http://www.broadinstitute.org/mpg/magenta/>). A gene was classified as “significant” if its p-value is less than 0.001. Each pathway is then tested for whether it contains more “significant” genes than expected by chance using a modified Fisher exact test.

RESULTS

The demographic and clinical characteristics of the samples are summarized in Table 1. After data quality control, 597,847 SNPs (81.8% of the total SNPs attempted in the array) were successfully genotyped. A total of 804 individuals with informative drug effect data (514 responders and 290 non-responders) had a set of high quality genotyped data with a call rate of 99.9%. Figure 1a shows a Q-Q plot. Of the 42 SNPs identified with a p-value <10⁻⁴, one SNP met the genome-wide significance level ($P = 1.76 \times 10^{-8}$) for SRI treatment response; six SNPs showed suggestive evidence of association at the level of $P < 10^{-5}$; and 35 SNPs showed signals of association at the level of $P < 10^{-4}$ (Figure 1b and Table 2).

The top-ranked SNP, rs17162912, is located in proximity (within a distance of ~13kb) to the Dispatched 1 gene (*DISP1*) ($P = 1.76 \times 10^{-8}$; OR = 0.39 [95% CI 0.26-0.58]) (Table 2 and Figure 2a left panel). Since there were no nearby markers with complete LD with rs17162912, we imputed genotypes in the left and right regions flanking rs17162912 (up to 250 kb) and carried out the association test. The results indicated that SNPs with strong LD with rs17162912 also presented suggestive association signals (Figure 2a right panel). We explored the integrated ENCODE regulation databases and found that rs17162912 is close to a peak (approximately 13kb) of the H3K27AC protein binding score, suggesting that this

region encompasses the promoter of *DISP1*. *DISP1* encodes a twelve trans-membrane domain protein that is required for long-range sonic hedgehog (Shh) secretion and transporting, which is important for the establishment of cell-cell contact and crucial for spinal cord development.³⁰

Among the suggestive signals, rs7676822 and rs1911877 located near the *PCDH10* gene (distance = 1,818kb and 1,772kb respectively) showed p-values of 2.86×10^{-6} (OR = 0.65 [95% CI 0.51-0.83]), and 8.41×10^{-6} (OR = 0.66 [95% CI 0.52-0.84]), respectively (Figure 2b). Due to the LD relationship between rs7676822 and rs1911877, these two SNPs should be counted as one hit. It is worth mentioning that *PCDH10* belongs to a protocadherin gene family consisting of the largest subgroup of the cadherin superfamily and mediates cell-cell adhesion and intracellular signaling. Most PCDHs (Protocadherins) are predominantly expressed in the central nervous system and have been suggested play pivotal roles in the formation and maintenance of synaptic functions.³¹

In order to comprehensively evaluate the role of some known pathways in the nervous system, we performed an enrichment analysis to test whether there are any genes significantly enriched in neuron signaling pathways. The results indicated that the glutamatergic neurotransmission pathway and the serotonergic neurotransmission pathway displayed more than two-fold enrichment. The glutamatergic signaling pathway had the highest enrichment score (Enrichment score = 3.38) and the best false discovery rate (FDR) (FDR = 0.0097), and the serotonergic neurotransmission pathway gave the second best enrichment score (Enrichment score = 2.39, FDR = 0.0213) (Table 3 and Supplementary Figure S1).

In the glutamatergic signaling pathway, there was a SNP rs7972211 near *GRIN2B* (N-methyl-D-aspartate receptor subunit 2B), a pivotal component of the glutamatergic neurotransmission system, showing a signal of association with SRI response, with $P = 2.71 \times 10^{-5}$ (OR = 0.65 [95% CI 0.49-0.87]) (Table 2). In addition to *GRIN2B*, *GPC6* (Glypican 6), another gene of the glutamatergic neurotransmission system, has three SNPs (rs17253738, rs9516369, rs3891616) exhibiting association signals, with $P = 2.13 \times 10^{-5}$ (OR = 0.59 [95% CI 0.43-0.82]); $P = 4.38 \times 10^{-5}$ (OR = 0.61 [95% CI 0.44-0.84]), and $P = 8.39 \times 10^{-5}$ (OR = 0.63 [95% CI 0.46-0.87]), respectively (Table 2 and Figure 2c). Due to the tight LD among these three SNPs, they serve as one hit. GPC6 promotes the glutamate receptor clustering and receptivity and induces the formation of postsynaptic signaling in the central nervous system (CNS) synapses. Depletion of GPC6 significantly reduces its function to induce postsynaptic activity.³² It was also interesting to observe that *DLGAP1* and *DLGAP2* support the enrichment (Supplementary Figure S1a). Of note, *DLGAP1* has been recently suggested as an OCD susceptibility gene.¹¹

In the serotonergic neurotransmission system, two within-LD ($R^2 = 0.6$) variants (rs722665 and rs2423366) in the *PLCBI* gene showed association at $P = 8.47 \times 10^{-5}$ (OR = 1.61 [95% CI 1.25-2.08]) and $P = 0.0001$, respectively. In addition, the protein kinase *PKC* harbors a SNP, rs11158347, showing association with $P = 5.18 \times 10^{-5}$ (OR = 1.83 [95% CI 1.39-2.41]) (Table 2 and Figure 2d). Furthermore, several well-established genes including *HTR2A* and *SLC6A4* appeared to support the enrichment (Supplementary Figure S1b).

DISCUSSION

In this study, we tested the association between genetic variations and treatment response in OCD. To date, this is the largest study on treatment response of OCD. While replication is warranted, this study represents an important step towards the comprehension of how genetic variants may contribute to the drug response in OCD treatment. The GWAS top SNP hit identified in this study is rs17162912 located near *DISP1*. In addition, our enrichment analysis indicated the roles of genes in the glutamatergic neurotransmission system (FDR = 0.0097) and the serotonergic system (FDR = 0.0213).

DISP1 is located in the 1q41-q42 locus which harbors a microdeletion related to a syndrome characterized by significant mental retardation, behavior problems, seizures, and characteristic dysmorphic features.³³ While rs17162912 is not within the gene regulators, it was found in close proximity of a promoter of the *DISP1* gene in ENCODE databases.

In addition to *DISP1*, another gene involved in cell-cell contact is *PCDH10*, an autism-spectrum disorders (ASD) related gene³⁴, provided suggestive level of association with SRI response. GWAS studies have shown that several PCDH genes are associated with neuropsychiatric disorders, including autism, bipolar disease and schizophrenia.³⁵ In our published OCD GWAS study¹², cadherin 10, type 2 (CDH10) was also reported as the second strongest association signal for OCD susceptibility. Collectively, these findings suggest that the cell-cell contact molecules might be involved in SRI response in OCD patients. However, due to the lack of adequate biological evidence in OCD to support this data-driven notion, future investigations are warranted.

Among the genes in the glutamatergic neurotransmission system, *GRIN2B*, an the NMDA (N-methyl-D-aspartate) glutamate receptor, emerged as one of the genes relevant to OCD and SRI response with some nominally significant SNPs. At least three previous genetic studies reported a significant association between a variant in *GRIN2B* and OCD.⁷⁻⁹ Volumetric magnetic resonance imaging suggested that genetic variations in *GRIN2B* are associated with regional volumetric brain abnormalities in OCD.³⁶ Preliminary results also suggest that *GRIN2B* variations interact with variations in *SLC1A1*³⁷, the susceptibility gene consistently replicated in OCD. However, our GWAs analysis did not provide strong evidence for any single variant association in the glutamatergic and serotonergic neurotransmission systems contributing to SRI response.

On the other hand, our enrichment analysis indicated that multiple genes in the glutamatergic and serotonergic neurotransmission system might jointly contribute to the outcome of SRI treatment in OCD (Table 3 and Supplementary Figure S1). More genes nominated occurred in the glutamatergic pathways than the ones in the serotonergic pathways. These genes are indicated in Supplementary Figures S1. However, we recognize that our study is under powered to identify all neuropathogenic SNPs for enrichment.

Despite obtaining one genome-wide significant hit and two suggestive pathway enrichment scores, several potential limitations of this study should be acknowledged. First, drug response was based on retrospective self-report. Second, given the rarity of large OCD samples with drug response information, the analysis was based on the limited sample size

available. Third, there was lack of detailed information on the dosage and duration of SRI medications, as well as receipt of behavioral therapy. Future studies, which measure treatment received in greater detail, and which evaluate response using reliable measures of symptom reduction within the first few months of treatment initiation, are needed to support a firm relationship between genetic variants and pathways and the SRI treatment effect in OCD.

On the other hand, several strengths of the current study should be noted. First, the rigorous semi-structured clinical examination and diagnostic best-estimation procedures support phenotypic reliability. Secondly, given the clinical, and assumed genetic heterogeneity of OCD, the OCGAS sample attempted to increase homogeneity by targeting recruitment on OCD-affected individuals with early age at onset. The fact that up to 30% OCD patients show minimal clinical improvement may reflect the biological heterogeneity of OCD phenotypes. Thus, consideration of the subgroups of OCD patients defined by drug response might provide a relatively more homogeneous population for clarification of the pathogenesis.³⁸ Finally, it is worth noting that study participants came from two studies, one of which was a family-based linkage study while the other was a trios-based association study. Although relatedness might confound association tests and odds ratio estimation, the MQLS test developed by Thornton and McPeck offers a better way to conduct a robust association test that corrects for the relatedness coefficients within pedigrees, using a kinship matrix (identity-by-descent, IBD) calculated from genotype data.²²

Further research is warranted to replicate the current findings on genetic variations related to SRI response in OCD-affected individuals. We anticipate that next-generation sequencing (NGS) methods, which facilitate the analysis of multiple genes including the effects of both common and rare variants³⁹, will provide further understanding of the mechanisms of OCD treatment response, and lead to more effective treatments for OCD.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGEMENTS

This project is a multiple sites collaborative project of OCD Collaborative Genetics Association Study (OC GAS), which is a collaboration among investigators at seven sites in the United States (namely Brown University, Columbia University, University of Southern California, Johns Hopkins University, Massachusetts General Hospital, University of California at Los Angeles, and the National Institute of Mental Health) funded by NIMH Grant Numbers: MH071507, MH079489, MH079487, MH079488, and MH079494. Qin and Shugart are both supported by IRP (Project number MH002930-04).

The views expressed in this presentation do not necessarily represent the views of the NIMH, NIH, HHS, or the United States Government.

REFERENCES

1. American Psychiatric Association. , editor. Diagnostic and statistical manual of mental disorders (DSM-IV). Psychiatric Press; Washington: 1994.
2. Nestadt G, Grados M, Samuels JF. Genetics of obsessive-compulsive disorder. *Psychiatr Clin North Am.* 2010; 33(1):141–158. [PubMed: 20159344]

3. Shugart YY, Samuels J, Willour VL, Grados MA, Greenberg BD, Knowles JA, et al. Genomewide linkage scan for obsessive-compulsive disorder: evidence for susceptibility loci on chromosomes 3q, 7p, 1q, 15q, and 6q. *Mol Psychiatry*. 2006; 11(8):763–770. [PubMed: 16755275]
4. Shugart YY, Wang Y, Samuels JF, Grados MA, Greenberg BD, Knowles JA, et al. A family-based association study of the glutamate transporter gene SLC1A1 in obsessive-compulsive disorder in 378 families. *Am J Med Genet B Neuropsychiatr Genet*. 2009; 150B(6):886–892. [PubMed: 19152386]
5. Voyiaziakis E, Evgrafov O, Li D, Yoon HJ, Tabares P, Samuels J, et al. Association of SLC6A4 variants with obsessive-compulsive disorder in a large multicenter US family study. *Mol Psychiatry*. 2012; 16(1):108–120. [PubMed: 19806148]
6. Murphy DL, Lesch KP. Targeting the murine serotonin transporter: insights into human neurobiology. *Nat Rev Neurosci*. 2008; 9(2):85–96. [PubMed: 18209729]
7. Arnold PD, Rosenberg DR, Mundo E, Tharmalingam S, Kennedy JL, Richter MA. Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. *Psychopharmacology (Berl)*. 2004; 174(4):530–538. [PubMed: 15083261]
8. Stewart SE, FJ.; Moorjani, J.; Jenike, E.; Beattie, K.; Illmann, C.; Delorme, R.; Leboyer, M.; Sedovic, M.; Smoller, J.; Jenike, M.; Pauls, D. Family-Based Association between Obsessive-Compulsive Disorder and Glutamate Receptor Candidate Genes. *World Congress of Psychiatric Genetics*; New York: 2007.
9. Alonso P, Gratacos M, Segalas C, Escaramis G, Real E, Bayes M, et al. Association between the NMDA glutamate receptor GRIN2B gene and obsessive-compulsive disorder. *J Psychiatry Neurosci*. 2012; 37(4):273–281. [PubMed: 22433450]
10. Taylor S. Molecular genetics of obsessive-compulsive disorder: a comprehensive meta-analysis of genetic association studies. *Mol Psychiatry*. 2013; 18(7):799–805. [PubMed: 22665263]
11. Stewart SE, Yu D, Scharf JM, Neale BM, Fagerness JA, Mathews CA, et al. Genome-wide association study of obsessive-compulsive disorder. *Mol Psychiatry*. 2013; 18(7):788–798. [PubMed: 22889921]
12. Mattheisen M, Samuels JF, Wang Y, Greenberg BD, Fyer AJ, McCracken JT et al. Genome-wide association study in obsessive-compulsive disorder: results from the OCGAS. *Mol Psychiatry*. 2014; 20:337–344.
13. Ferguson JM. SSRI Antidepressant Medications: Adverse Effects and Tolerability. *Prim Care Companion J Clin Psychiatry*. 2001; 3(1):22–27. [PubMed: 15014625]
14. Di Bella D, Erzegovesi S, Cavallini MC, Bellodi L. Obsessive-Compulsive Disorder, 5-HTTLPR polymorphism and treatment response. *Pharmacogenomics J*. 2002; 2(3):176–181. [PubMed: 12082589]
15. Brandl EJ, Tiwari AK, Zhou X, Deluce J, Kennedy JL, Muller DJ, et al. Influence of CYP2D6 and CYP2C19 gene variants on antidepressant response in obsessive-compulsive disorder. *Pharmacogenomics J*. 2014; 14(2):176–181. [PubMed: 23545896]
16. Brandl EJ, Muller DJ, Richter MA. Pharmacogenetics of obsessive-compulsive disorders. *Pharmacogenomics*. 2012; 13(1):71–81. [PubMed: 22176623]
17. Sangkuhl K, Klein TE, Altman RB. Selective serotonin reuptake inhibitors pathway. *Pharmacogenet Genomics*. 2009; 19(11):907–909. [PubMed: 19741567]
18. Tansey KE, Guipponi M, Perroud N, Bondolfi G, Domenici E, Evans D, et al. Genetic predictors of response to serotonergic and noradrenergic antidepressants in major depressive disorder: a genome-wide analysis of individual-level data and a meta-analysis. *PLoS Med*. 2012; 9(10):e1001326. [PubMed: 23091423]
19. Samuels JF, Riddle MA, Greenberg BD, Fyer AJ, McCracken JT, Rauch SL, et al. The OCD collaborative genetics study: methods and sample description. *Am J Med Genet B Neuropsychiatr Genet*. 2006; 141B(3):201–207. [PubMed: 16511842]
20. Nestadt G, Wang Y, Grados MA, Riddle MA, Greenberg BD, Knowles JA, et al. Homeobox genes in obsessive-compulsive disorder. *Am J Med Genet B Neuropsychiatr Genet*. 2011; 159B(1):53–60. [PubMed: 22095678]

21. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. *Arch Gen Psychiatry*. 1989; 46(11):1006–1011. [PubMed: 2684084]
22. Thornton T, McPeck MS. Case-control association testing with related individuals: a more powerful quasi-likelihood score test. *Am J Hum Genet*. 2007; 81(2):321–337. [PubMed: 17668381]
23. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*. 2007; 81(3):559–575. [PubMed: 17701901]
24. Chelala C, Khan A, Lemoine NR. SNPnexus: a web database for functional annotation of newly discovered and public domain single nucleotide polymorphisms. *Bioinformatics*. 2009; 25(5):655–661. [PubMed: 19098027]
25. Hindorf LA, MJ.; Morales, J.; Junkins, HA.; Hall, PN.; Klemm, AK.; Manolio, TA. [Jan 23, 2013] A Catalog of Published Genome-Wide Association Studies. URL: www.genome.gov/gwastudies.
26. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics*. 2010; 26(18):2336–2337. [PubMed: 20634204]
27. Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. *Bioinformatics*. 2003; 19(1):149–150. [PubMed: 12499305]
28. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. *Genome Biol*. 2003; 4(5):P3. [PubMed: 12734009]
29. Segre AV, Groop L, Mootha VK, Daly MJ, Altshuler D. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. *PLoS Genet*. 2010; 6(8)
30. Etheridge LA, Crawford TQ, Zhang S, Roelink H. Evidence for a role of vertebrate *Disp1* in long-range *Shh* signaling. *Development*. 2010; 137(1):133–140. [PubMed: 20023168]
31. Kim SY, Chung HS, Sun W, Kim H. Spatiotemporal expression pattern of non-clustered protocadherin family members in the developing rat brain. *Neuroscience*. 2007; 147(4):996–1021. [PubMed: 17614211]
32. Allen NJ, Bennett ML, Foo LC, Wang GX, Chakraborty C, Smith SJ, et al. Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors. *Nature*. 2012; 486(7403):410–414. [PubMed: 22722203]
33. Jun KR, Hur YJ, Lee JN, Kim HR, Shin JH, Oh SH, et al. Clinical characterization of *DISP1* haploinsufficiency: A case report. *Eur J Med Genet*. 2013
34. Morrow EM, Yoo SY, Flavell SW, Kim TK, Lin Y, Hill RS, et al. Identifying autism loci and genes by tracing recent shared ancestry. *Science*. 2008; 321(5886):218–223. [PubMed: 18621663]
35. Redies C, Hertel N, Hubner CA. Cadherins and neuropsychiatric disorders. *Brain Res*. 2012; 1470:130–144. [PubMed: 22765916]
36. Arnold PD, Macmaster FP, Hanna GL, Richter MA, Sicard T, Burroughs E, et al. Glutamate system genes associated with ventral prefrontal and thalamic volume in pediatric obsessive-compulsive disorder. *Brain Imaging Behav*. 2009; 3(1):64–76. [PubMed: 21031159]
37. Cai J, Zhang W, Yi Z, Lu W, Wu Z, Chen J, et al. Influence of polymorphisms in genes *SLC1A1*, *GRIN2B*, and *GRIK2* on clozapine-induced obsessive-compulsive symptoms. *Psychopharmacology (Berl)*. 2013; 230(1):49–55. [PubMed: 23660601]
38. Davis, KL.; Charney, D.; Coyle, JT.; Nemeroff, C. *Neuropsychopharmacology: The Fifth Generation of Progress*. Lippincott Williams & Wilkins; Philadelphia: 2002.
39. Korf BR, Rehm HL. New approaches to molecular diagnosis. *JAMA*. 2013; 309(14):1511–1521. [PubMed: 23571590]




Figure 1. Genome-wide association study of genetic variations and treatment response. (a) Q-Q plot for the association test of genetic variations. (b) Manhattan plot for the association test of genetic variations and SRI response. MQLS test was performed to test the association of variants associated with drug response. A red line indicates genome-wide significance (5×10^{-8}); a blue line indicates the level of suggestive evidence for association (1×10^{-5}).




Figure 2. Regional association plot with LD illustrated for significant SNPs. **(a)** SNAP plot of rs17162912 for the association test (left) and for the association test after the imputed SNPs were included (right). **(b)** SNAP plot of rs7676822, rs17253738 **(c)** and rs722665 **(d)**.

Table 1

Characteristics of OCD participants

Group	Subgroup	Count (N = 804)	Frequency
Sex	Male	312	0.39
	Female	492	0.61
Age ^a	7-9	19	0.02
	10-19	189	0.23
	20-29	170	0.21
	30-39	173	0.22
	40-49	159	0.20
	50-78	94	0.12
	Age at onset of OC symptoms		
	5-9	518	0.64
	10-19	237	0.30
	20-44	118	0.06
SRI response ^b	“No response”	290	0.36
	“Response”	514	0.64

^aAge unknown for 5 participants.

^b“Couldn't tolerate” and “Unknown” were excluded from data analysis.

Table 2

Top loci associated with treatment response in OCD patients

SNP	Chr.	Position	A1/A2 ^a	Resp. ^b	Non-Resp. ^b	P ^c	OR(95%CI) ^d	Region	Nearest Gene (distance/bp)
rs17162912	1	222974926	C/T	0.06	0.15	1.76×10 ⁻⁸	0.39(0.26-0.58)	intergenic	<i>DISP1(13505)</i>
rs9303380	17	54117492	A/G	0.03	0.07	1.03×10 ⁻⁶	0.37(0.21-0.64)	intergenic	<i>ANKFN1(113344)</i>
rs12437601	15	98687330	C/T	0.09	0.03	1.66×10 ⁻⁶	4.07(2.16-7.66)	intergenic	<i>ARRDC4(170262)</i>
rs16988159	21	32727653	C/T	0.3	0.42	2.48×10 ⁻⁶	0.57(0.45-0.73)	intronic	<i>TIAMI</i>
rs7676822	4	132252355	G/T	0.28	0.39	2.86×10 ⁻⁶	0.65(0.51-0.83)	intergenic	<i>PCDH10(1818115)</i>
rs723815	6	52519203	A/C	0.2	0.11	3.50×10 ⁻⁶	2.06(1.46-2.9)	intergenic	<i>LOC730101(9996)</i>
rs1911877	4	132298239	C/T	0.3	0.4	8.41×10 ⁻⁶	0.66(0.52-0.84)	intergenic	<i>PCDH10(1772231)</i>
rs8081611	17	4813365	C/T	0.12	0.05	1.40×10 ⁻⁵	2.59(1.6-4.19)	intergenic	<i>CHRNE(6996)</i>
rs7972963	12	66646199	T/G	0.08	0.14	1.50×10 ⁻⁵	0.54(0.37-0.78)	UTR3	<i>IRAK3</i>
rs17253738	13	94874089	A/G	0.14	0.21	2.13×10 ⁻⁵	0.59(0.43-0.82)	intronic	<i>GPC6</i>
rs2706652	11	12289058	A/G	0.42	0.33	2.30×10 ⁻⁵	1.5(1.18-1.92)	intergenic	<i>MICAL2(3727)</i>
rs7972211	12	14269986	G/A	0.16	0.23	2.71×10 ⁻⁵	0.65(0.49-0.87)	intergenic	<i>GRIN2B(136964)</i>
rs318982	11	131415267	T/C	0.21	0.29	2.82×10 ⁻⁵	0.65(0.5-0.86)	intronic	<i>NTM</i>
rs6918918	6	52515078	T/C	0.22	0.13	3.17×10 ⁻⁵	1.94(1.4-2.68)	intergenic	<i>LOC730101(14121)</i>
rs11022029	11	11806317	C/T	0.13	0.2	3.18×10 ⁻⁵	0.65(0.48-0.87)	intergenic	<i>USP47(56653)</i>
rs881499	7	30976064	C/T	0.25	0.36	3.58×10 ⁻⁵	0.55(0.42-0.72)	intergenic	<i>AQP1(10933)</i>
rs905690	3	68725295	T/C	0.35	0.26	3.79×10 ⁻⁵	1.56(1.2-2.02)	intergenic	<i>FAM19A4(55620)</i>
rs12561532	13	52108978	G/A	0.06	0.12	3.81×10 ⁻⁵	0.48(0.32-0.72)	intergenic	<i>MIR4703(17747)</i>
rs9516369	13	94868584	G/A	0.14	0.21	4.38×10 ⁻⁵	0.61(0.44-0.84)	intronic	<i>GPC6</i>
rs7214776	17	4811615	C/T	0.12	0.06	4.39×10 ⁻⁵	2.4(1.51-3.83)	intergenic	<i>CHRNE(5246)</i>
rs9365319	6	162114707	T/C	0.13	0.21	4.49×10 ⁻⁵	0.57(0.42-0.77)	intronic	<i>PARK2</i>
rs7004833	8	11840011	G/A	0.05	0.1	4.53×10 ⁻⁵	0.47(0.3-0.75)	intronic	<i>DEFB135</i>
rs4768165	12	40025034	A/G	0.25	0.34	4.79×10 ⁻⁵	0.66(0.51-0.85)	intronic	<i>C12orf40</i>
rs6005451	22	27852183	C/T	0.09	0.16	4.85×10 ⁻⁵	0.53(0.37-0.75)	intergenic	<i>MNI(292082)</i>
rs10894396	11	131326035	A/G	0.41	0.29	4.91×10 ⁻⁵	1.72(1.34-2.22)	intronic	<i>NTM</i>
rs2293223	2	103035468	T/C	0.15	0.24	4.92×10 ⁻⁵	0.6(0.44-0.8)	intronic	<i>IL18RAP</i>
rs1403552	2	103088777	A/G	0.15	0.24	5.00×10 ⁻⁵	0.59(0.44-0.79)	upstream	<i>SLC9A4</i>
rs11158347	14	61930678	A/G	0.33	0.21	5.18×10 ⁻⁵	1.83(1.39-2.41)	intronic	<i>PRKCH</i>
rs7706447	5	116513164	C/A	0.04	0.1	5.83×10 ⁻⁵	0.36(0.23-0.59)	intergenic	<i>LOC728342(238044)</i>
rs11611119	12	40166257	C/T	0.35	0.26	5.83×10 ⁻⁵	1.59(1.22-2.07)	intronic	<i>SLC2A13</i>
rs4596498	6	139540103	A/G	0.24	0.16	6.36×10 ⁻⁵	1.73(1.26-2.36)	intergenic	<i>TXLNB(21096)</i>
rs7565966	2	179742232	C/T	0.45	0.33	6.69×10 ⁻⁵	1.63(1.28-2.08)	intronic	<i>CCDC141</i>
rs12974044	19	42368629	G/A	0.37	0.27	7.07×10 ⁻⁵	1.56(1.2-2.02)	intronic	<i>RPS19</i>
rs139531	22	41676176	G/A	0.3	0.2	7.07×10 ⁻⁵	1.69(1.28-2.24)	intronic	<i>RANGAPI</i>
rs1471659	3	126812577	G/A	0.11	0.17	7.74×10 ⁻⁵	0.61(0.43-0.85)	intergenic	<i>PLXNA1(56342)</i>
rs4933958	10	85821027	C/T	0.29	0.21	8.04×10 ⁻⁵	1.56(1.18-2.05)	intergenic	<i>GHITM(78158)</i>
rs10013818	4	44293409	T/C	0.26	0.18	8.34×10 ⁻⁵	1.6(1.19-2.15)	intronic	<i>KCTD8</i>

SNP	Chr.	Position	A1/A2 ^a	Resp. ^b	Non-Resp. ^b	P ^c	OR(95%CI) ^d	Region	Nearest Gene (distance/bp)
rs3891616	13	94866849	C/A	0.14	0.2	8.39×10 ⁻⁵	0.63(0.46-0.87)	intronic	<i>GPC6</i>
rs722665	20	8508604	C/T	0.4	0.29	8.47×10 ⁻⁵	1.61(1.25-2.08)	intronic	<i>PLCB1</i>
rs2295394	14	93412743	T/C	0.04	0.08	8.55×10 ⁻⁵	0.48(0.29-0.79)	NA	NA
rs351098	4	132409029	T/C	0.22	0.3	8.77×10 ⁻⁵	0.67(0.51-0.86)	intergenic	<i>PCDH10(1661441)</i>
rs12532545	7	141875267	A/C	0.17	0.25	9.21×10 ⁻⁵	0.63(0.48-0.84)	intronic	<i>LOC100124692</i>

Abbreviations: Chr, chromosome number; A1/A2 OR, odds ration; CI confidence interval; MQLS, a more powerful quasi-likelihood score test.

^aA1/A2, in which "A1" is minor allele, "A2" is major allele.

^bResp., minor allele frequency (MAF) for the patients response to SSRIs; Non-Resp., MAF for the patients non-response to SSRIs.

^cMQLS_{Robust} p-value, cut-off p-value threshold was set 1×10⁻⁴ for the risk allele.

^dLogistic regression model was performed on probands, adjusted by sex, age. Cut-off threshold was set at OR 1.5 for the risk allele.

Table 3

Enrichment analysis results in ten neurologically-relevant pathways

Pathways examined	Genes Enriched	Enrichment Score	P-value	FDR
Glutamatergic signaling	14	3.38	0.0009	0.0097
Serotonergic signaling	11	2.39	0.0047	0.0213
Long-term potentiation	6	1.55	0.0058	0.0213
Neurotrophin signaling pathway	8	1.54	0.0120	0.0330
Long-term depression	4	1.04	0.0280	0.0512
GABAergic signaling	7	1.12	0.0340	0.0512
Dopaminergic synapse	7	1.02	0.0346	0.0511
Retrograde endocannabinoid signaling	6	0.88	0.0372	0.0512
Cholinergic signaling	4	0.67	0.5720	0.6292
Synaptic vesicle cycle	3	0.34	0.9280	0.9281

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript